Mitsubishi Tanabe Pharma America Announces More Than 10,000 People with ALS Treated with RADICAVA ORS® (edaravone) and/or RADICAVA® (edaravone)

Mitsubishi Tanabe Pharma America Announces More Than 10,000 People with ALS Treated with RADICAVA ORS® (edaravone) and/or RADICAVA® (edaravone)

Mitsubishi Tanabe Pharma America (MTPA) announced that more than 10,000 people with amyotrophic lateral sclerosis (ALS) have been treated with RADICAVA ORS® (edaravone) and/or RADICAVA® (edaravone) in the United States since its launch in May 2017.

The milestone was reached as the Food and Drug Administration (FDA) approved the use of RADICAVA ORS®/RADICAVA® for the treatment of ALS in May 2017. This FDA approval marked the first new ALS therapy to receive approval in more than two decades.

RADICAVA ORS®/RADICAVA® is a novel intravenous therapy that has been proven to reduce the rate of functional decline in ALS patients. This therapy works by reducing the production of free radicals, which can damage the nerve cells and lead to the progressive loss of muscle strength and mobility characteristic of ALS.

Since its launch, RADICAVA ORS®/RADICAVA® has been adopted by many ALS patients and their healthcare providers in the United States. According to MTPA, the number of patients treated with the therapy has grown significantly since its launch, and more than 10,000 people with ALS have been treated with the drug in the United States.

“Reaching this milestone is a testament to the dedication of the ALS community and their healthcare providers to seek out new treatments for this devastating neurodegenerative disease,” said MTPA President and CEO Tom Isett. “We are proud to be able to provide a novel therapy that has been proven to reduce the rate of functional decline in ALS patients.”

Isett also noted that MTPA is committed to continuing to support the ALS community and their healthcare providers to ensure the best possible outcomes for ALS patients.

“We remain committed to providing access to RADICAVA ORS®/RADICAVA® for people with ALS and ensuring that healthcare providers have the necessary resources to effectively manage and treat their patients,” Isett said.

In commemoration of this milestone, MTPA will launch an awareness campaign to highlight the progress in treating ALS over the past two decades.

Mitsubishi Tanabe Pharma America has announced that greater than 10,000 individuals with amyotrophic lateral sclerosis (ALS) have been treated with RADICAVA ORS® (edaravone) and/or RADICAVA® (edaravone) since its authorization by the Food and Drug Administration (FDA) in May 2017. This marks the first novel ALS therapy to be approved in more than two decades.

RADICAVA ORS®/RADICAVA® is an intravenous therapy which has empirically been demonstrated to reduce the rate of functional decline in those afflicted with ALS. This therapeutic approach works by decreasing the release of free radicals, which can harm nerve cells and lead to the progressive weakening and lack of mobility characteristic of ALS.

Since its release, RADICAVA ORS®/RADICAVA® has been increasingly adopted by ALS patients and their healthcare providers all throughout the US. Thomas Isett, President and CEO of MTPA, stated, “Reaching this milestone is an affirmation of the commitment of the ALS community and their healthcare providers to search for novel treatments for this devastating neurodegenerative disease.” He continued, “We are proud to offer a therapy which has been shown to reduce the rate of functional decline in ALS patients.”

Isett also emphasized MTPA’s steadfast dedication to providing access to RADICAVA ORS®/RADICAVA® for those with ALS and ensuring that healthcare providers have the necessary resources to effectively manage and treat their patients. To celebrate this milestone, MTPA has launched an awareness campaign to emphasize the success in treating ALS over the past two decades.